189298-13-3 Usage
General Description
4-(3-Hydroxy-2-phenyl-propyl)-piperazine-1-carboxylic acid tert-butyl ester, also known as tbo-filgrastim, is a synthetic derivative of the naturally occurring human granulocyte colony-stimulating factor (G-CSF). It is typically used as a medication to stimulate the production of white blood cells in patients undergoing chemotherapy or bone marrow transplant. The tert-butyl ester group in the chemical structure enhances its stability and prolongs its circulation time in the body. Tbo-filgrastim works by stimulating the bone marrow to produce more white blood cells, helping to prevent infections in patients with compromised immune systems. It is administered as an injection and is generally considered safe, with common side effects including bone pain, headache, and muscle pain.
Check Digit Verification of cas no
The CAS Registry Mumber 189298-13-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,8,9,2,9 and 8 respectively; the second part has 2 digits, 1 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 189298-13:
(8*1)+(7*8)+(6*9)+(5*2)+(4*9)+(3*8)+(2*1)+(1*3)=193
193 % 10 = 3
So 189298-13-3 is a valid CAS Registry Number.
189298-13-3Relevant articles and documents
Substituted indolylpropyl-piperazine derivatives as 5-HT1D α agonists
-
, (2008/06/13)
A class of 1-[3-(1H-indol-3-yl)propyl]-4-(2-phenylethyl)piperazine derivatives, substituted at the 5-position of the indole nucleus by a five-membered heteroaromatic moiety, on one or other of the ethylene carbon atoms of the phenethyl moiety by halogen, trifluoromethyl, alkyl, hydroxyalkyl or alkoxyalkyl, and optionally on the phenyl ring of the phenethyl moiety by halogen, trifluoromethyl, alkoxy or an oxazolidinone group and optionally by one or two further substituents, are selective agonists of 5-HT1 -like receptors, being potent agonists of the human 5-HT1D α receptor subtype whilst possessing at least a 10-fold selective affinity for the 5-HT1D α receptor subtype relative to the 5-HT1D β subtype; they are therefore useful in the treatment and/or prevention of clinical conditions, in particular migraine and associated disorders, for which a subtype-selective agonist of 5-HT1D receptors is indicated, whilst eliciting fewer side-effects, notably adverse cardiovascular events, than those associated with non-subtype-selective 5-HT1D receptor agonists.
